Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
–PRIME status is supported by positive data from the Phase 2b ENLIVEN trial of pegozafermin– –Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic MASH (fibrosis stage F2-F3) patients is enrolling and ENLIGHTEN-Cirrhosis in MASH patients with compensated cirrhosis (F4) is planned to initiate in the second quarter of 2024– SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innova
Madrigal and other companies focused on treating fatty liver disease won’t get sidelined by obesity drugs.
In this article, we’re going to take a look at 13 best biotech stocks to buy under $20. To see more stocks that made the list, you can skip ahead and jump straight to the top 5 best biotech stocks to buy under $20. When it comes to investing, few industries are as exciting to […]
—Co-primary endpoints in ENLIGHTEN-Fibrosis assessed at week 52 will potentially support accelerated approval in non-cirrhotic MASH (fibrosis stage F2-F3) patients— —ENLIGHTEN-Cirrhosis, the second trial in the program, is planned to evaluate patients with compensated cirrhosis (F4) and is expected to initiate in the second quarter of 2024— SAN FRANCISCO, March 12, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and comme
SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 10,800 shares of the Company’s common stock to a new employe
SAN FRANCISCO, March 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 at 1:40 PM EST and participate in one-on-one investor meetings. The webcast of the fires
Akero (AKRO) reports positive results from its mid-stage study of efruxifermin in pre-cirrhotic metabolic dysfunction-associated steatohepatitis patients at week 96. The stock gains 12%.
The average of price targets set by Wall Street analysts indicates a potential upside of 121.5% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is it a good or bad thing when a stock surpasses resistance at the 200-day simple moving average?
Biotech stocks Akero Therapeutics and 89bio rocketed Monday after the former announced promising test results for a liver disease treatment.